Marinus Pharmaceuticals Announces New Method Of Use Patent Granted For IV Ganaxolone By USPTO In Status Epilepticus
Portfolio Pulse from Happy Mohamed
Marinus Pharmaceuticals (NASDAQ: MRNS) has been granted a new method of use patent by the USPTO for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. This is the company's second method of use patent for IV ganaxolone in SE, further strengthening its intellectual property position.
June 21, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals has been granted a new method of use patent for IV ganaxolone in status epilepticus treatment, further strengthening its intellectual property position.
The new patent granted by the USPTO for IV ganaxolone in status epilepticus treatment strengthens Marinus Pharmaceuticals' intellectual property position. This is likely to have a positive impact on the company's stock price in the short term, as it demonstrates the company's commitment to innovation and protecting its commercial potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100